Bremelanotide FAQ: common questions answered
An as-needed injection for low libido before menopause; nausea is common.
Also called: PT-141, PT141, Vyleesi.
Melanocortin agonists · Melanocortin receptor agonist · Evidence: Approved drug.
- Is Bremelanotide FDA-approved? Yes: Vyleesi (acquired, generalized HSDD in premenopausal women.). Not approved for men, postmenopausal women, sexual performance or weight loss. No separate 503B bulks-list entitlement was confirmed.
- How do people take it? Under the skin, as needed; no more than one dose within 24 hours. Stop after 8 weeks if symptoms have not improved.. Source: drug label.
- What's the difference between Bremelanotide and Melanotan II? Bremelanotide: an as-needed injection for low libido before menopause; nausea is common. Melanotan II: an unapproved tanning peptide with small human trials and reports of serious harm. Why people pair them: some users report concurrent libido and tanning use.
- Can I take it with Melanotan II? Some users report concurrent libido and tanning use. Overlapping melanocortin effects; no controlled safety evidence for the combination. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? No, it is not on the banned list (WADA 2026). Inferred from the 2026 list and human drug approval: no named ban found, and S0 does not apply to an approved substance. Verify the exact product.
- How do I store it once opened? Ready-made single-dose solution; discard the device after use.
Related to Bremelanotide
- Melanotan II: An unapproved tanning peptide with small human trials and reports of serious harm.
- Melanotan I / Afamelanotide: The molecule in an approved EPP implant; online tanning powder is a different formulation.
- Setmelanotide: A daily injection approved for specific genetic obesity and acquired hypothalamic obesity.
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- Scenesse, INN-afamelanotide, 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- DailyMed - VYLEESI- bremelanotide injection, 2025
- Priapism (painful erections) - NHS, NHS · 2023
- NDA 210557 Multi-disciplinary Review and Evaluation: Vyleesi (bremelanotide), 2019
- Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options., Toledo RG et al. · Journal of minimally invasive gynecology · 2026
- Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials., Spana C et al. · Diabetes, obesity & metabolism · 2022
- Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women., Spielmans GI et al. · Journal of sex research · 2021
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials., Kingsberg SA et al. · Obstetrics and gynecology · 2019
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder., Simon JA et al. · Obstetrics and gynecology · 2019
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.